Possibility of Using the Interferon Gamma Release Level As a DynamicBiomarker

The potential of using interferon-γ (IFN-γ) release as a biomarker was examined in the previous study. Twenty-nine patients treated with immune checkpoint inhibitors were divided into three groups according to their IFN-γ release level in the positive control after enzyme-linked immunosorbent assay. The three groups showed clear differences in clinical outcomes. IGR can be a new dynamic biomarker to determine the immunological status of a patient at the pretreatment stage or any change in the state of their immunity during the treatment of various diseases.